Genetics and biology of pancreatic ductal adenocarcinoma

With 5-year survival rates remaining constant at 6% and rising incidences associated with an epidemic in obesity and metabolic syndrome, pancreatic ductal adenocarcinoma (PDAC) is on track to become the second most common cause of cancer-related deaths by 2030. The high mortality rate of PDAC stems primarily from the lack of early diagnosis and ineffective treatment for advanced tumors. During the past decade, the comprehensive atlas of genomic alterations, the prominence of specific pathways, the preclinical validation of such emerging targets, sophisticated preclinical model systems, and the molecular classification of PDAC into specific disease subtypes have all converged to illuminate drug discovery…

• UD
  U.S. Department of Defense

  Awards: W81XWH-11-1-, W81XWH, U01DK108328, W81XWH-14-1-0429, W81XWH-11-1-0418, U01CA196403
• AA
  American Association for Cancer Research

  Award: W81XWH-11-1-0418
• AC
  American Cancer Society

  Awards: R01CA157490, R01GM095567, R01CA188048
• NI
  National Institutes of Health

  Awards: 14-90-25-DRAE, P01CA117969, U01DK108328, U01CA196403, R01CA188048, W81XWH, R01GM095567, R01CA157490
• UO
  University of Texas MD Anderson Cancer Center

  Award: RSG-13-298-01-TBG